Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

LOSS PER SHARE

LOSS PER SHARE

3 Months Ended

Dec. 31, 2018

9. LOSS PER SHARE

Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders less the current period preferred stock dividend by the weighted average common shares outstanding during the period. Diluted earnings (loss) per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock

A summary of the net income (loss) and shares used to compute net income (loss) per share for the three months ended December 31, 2018 and 2017 is as follows:

	Three Months Ended
	December 31,
	2018			2017
Net loss for computation of basic and diluted net loss per share:
Net Loss attributable to MYnd Analytics, Inc.	$	(2,377,500	)	$	(2,769,300	)
Preferred stock dividends		(24,600	)		—
	$	(2,402,100	)	$	(2,769,300	)

Basic and diluted net loss per share:
Basic and diluted net loss per share	$	(0.32	)	$	(0.64	)
Basic and diluted weighted average shares outstanding		7,542,663			4,332,927

Anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Warrants		6,075,769			4,567,672
Restricted common stock		550,564			254,333
Options		1,622,445			559,617
Total		8,248,778			5,381,622